New advance in the biological treatment of inflammatory bowel disease

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorHong, HyeJung
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentDrimba, László
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.opponentdeptKenézy Kórház Központi Aneszteziológiai és Intezív Terápiás Osztályhu_HU
dc.date.accessioned2020-02-24T10:25:03Z
dc.date.available2020-02-24T10:25:03Z
dc.date.created2019-05-31
dc.description.abstractThe pharmacological treatment of inflammatory bowel disease (IBD) over the last two decades has transitioned from treatment with aminosalycilates, corticosteroids and immunomodulators to treatment with anti-tumor necrosis factor (anti-TNF) therapy. Nevertheless, anti-TNF therapy is discontinued in 20-30% of patients for primary non-response and in another 30-40% for losing response within one year of treatment. Pharmacokinetic (antidrug antibodies and/or low drug concentrations) or pharmacodynamic issues which is characterized by a non-TNF driven inflammation attribute undesirable therapeutic outcomes. The use of medications with different mechanisms of action is necessitated by the latter issues. Besides the biologics natalizumab, vedolizumab and ustekinumab have been investigated as treatment of IBD new non-anti-TNF therapies, including small molecule drugs against Janus kinase and sphingosine-1-phosphate receptors. New advanced biological medication that are in the later stages of development for the treatment of IBD and directed against immune targets other than TNF will be reviewed by this manuscript.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent39hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/281192
dc.language.isoenhu_HU
dc.subjectnew biological treatmenthu_HU
dc.subjectinflammatory bowel disease
dc.subject.dspaceDEENK Témalista::Orvostudomány::Farmakológiahu_HU
dc.titleNew advance in the biological treatment of inflammatory bowel diseasehu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)